Employees: 11 (2023.0)Legal category: 5485Size: PMECreation date: 2019-10-22 (6 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: ALES (30100), Gard
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
LA GRANDE PHARMACIE DU CENTR'ALES : revenue, balance sheet and financial ratios
LA GRANDE PHARMACIE DU CENTR'ALES is a French company
founded 6 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in ALES (30100),
this company of category PME
shows in 2022 a revenue of 3.5 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - LA GRANDE PHARMACIE DU CENTR'ALES (SIREN 878383009)
Indicator
2024
2023
2022
2021
2020
Revenue
N/C
N/C
3 452 858 €
N/C
N/C
Net income
180 405 €
119 391 €
204 912 €
249 956 €
30 685 €
EBITDA
N/C
N/C
330 881 €
N/C
N/C
Net margin
N/C
N/C
5.9%
N/C
N/C
Revenue and income statement
In 2024, LA GRANDE PHARMACIE DU CENTR'ALES generates positive net income of 180 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2020-2024: 31 k€ -> 180 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
180 405 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 54%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 55%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
53.525%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
55.465%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution LA GRANDE PHARMACIE DU CENTR'ALES
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2020
2021
2022
2023
2024
Debt ratio
118.268
73.786
57.488
68.47
53.525
Financial autonomy
38.371
43.847
54.242
50.756
55.465
Repayment capacity
None
None
4.78
None
None
Cash flow / Revenue
None%
None%
6.041%
None%
None%
Sector positioning
Debt ratio
53.522024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Good+6 pts over 3 years
In 2024, the debt ratio of LA GRANDE PHARMACIE DU CE... (53.52) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
55.47%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good
In 2024, the financial autonomy of LA GRANDE PHARMACIE DU CE... (55.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
4.78 years2022
2022
Q1: 1.29 years
Med: 3.55 years
Q3: 6.63 years
Average
In 2022, the repayment capacity of LA GRANDE PHARMACIE DU CE... (4.78) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 181.94. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
181.945
Liquidity indicators evolution LA GRANDE PHARMACIE DU CENTR'ALES
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2020
2021
2022
2023
2024
Liquidity ratio
194.969
153.881
213.464
173.325
181.945
Interest coverage
None
None
3.333
None
None
Sector positioning
Liquidity ratio
181.942024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Average
In 2024, the liquidity ratio of LA GRANDE PHARMACIE DU CE... (181.94) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
3.33x2022
2022
Q1: 0.75x
Med: 2.51x
Q3: 5.16x
Good
In 2022, the interest coverage of LA GRANDE PHARMACIE DU CE... (3.3x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution LA GRANDE PHARMACIE DU CENTR'ALES
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
537 230 €
0 €
0 €
Inventory turnover (days)
0
0
45
0
0
Customer payment term (days)
0
0
7
0
0
Supplier payment term (days)
0
0
48
0
0
Positioning of LA GRANDE PHARMACIE DU CENTR'ALES in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of LA GRANDE PHARMACIE DU CENTR'ALES is estimated at
2 518 587 €
(range 1 753 904€ - 3 767 950€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1753k€2518k€3767k€
2 518 587 €Range: 1 753 904€ - 3 767 950€
NAF 5 année 2024
Valuation method used
Net Income Multiple
180 405 €
×
14.0x
=2 518 587 €
Range: 1 753 904€ - 3 767 951€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare LA GRANDE PHARMACIE DU CENTR'ALES with other companies in the same sector:
Frequently asked questions about LA GRANDE PHARMACIE DU CENTR'ALES
What is the revenue of LA GRANDE PHARMACIE DU CENTR'ALES ?
The revenue of LA GRANDE PHARMACIE DU CENTR'ALES in 2022 is 3.5 M€.
Is LA GRANDE PHARMACIE DU CENTR'ALES profitable?
Yes, LA GRANDE PHARMACIE DU CENTR'ALES generated a net profit of 180 k€ in 2024.
Where is the headquarters of LA GRANDE PHARMACIE DU CENTR'ALES ?
The headquarters of LA GRANDE PHARMACIE DU CENTR'ALES is located in ALES (30100), in the department Gard.
Where to find the tax return of LA GRANDE PHARMACIE DU CENTR'ALES ?
The tax return of LA GRANDE PHARMACIE DU CENTR'ALES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does LA GRANDE PHARMACIE DU CENTR'ALES operate?
LA GRANDE PHARMACIE DU CENTR'ALES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart